CyPath Lung Sales Double Through Q3 2026; New VA-Focused Distribution Deal
BIAF sits 30% above its 52-week low of $4.56.
Summary
bioAffinity Technologies reported CyPath Lung sales more than doubled through Q3 2026, with 1,620 tests delivered versus 775 a year earlier, and announced a new distribution agreement with AvMEDICAL targeting the VA and government healthcare system.
Updates
· BusinessWire — CEO Maria Zannes highlighted the 100% Q3 sales increase and the AvMEDICAL distribution agreement's potential to broaden government healthcare reach.
Key Events · Earnings and Guidance · BIAF
-
CyPath Lung Sales Double Through Q3
Sales increased more than 100% through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 in the prior-year period.
-
Physician Adoption Expands Sharply
Ordering physicians grew 89% year-over-year in Q3 2026, and existing prescribers increased utilization by 48%.
-
New AvMEDICAL Distribution Agreement
New distribution agreement with Veteran-Owned AvMEDICAL targets the government healthcare system, including the Department of Veterans Affairs.
-
Going-Concern Backdrop
The growth comes as the company operates under a going-concern warning with a cash runway that was projected to end around August 2026, making commercial traction critical to avoiding further dilutive financing.
Analysis · BIAF · Industrial Applications And Services
bioAffinity reported CyPath Lung sales more than doubled through Q3 2026 versus 2025, with 1,620 tests delivered compared to 775 a year earlier. Ordering physicians grew 89% and existing prescribers increased utilization by 48%. The company also announced a new distribution agreement with Veteran-Owned AvMEDICAL targeting the government healthcare system, including the Department of Veterans Affairs. This matters because the company is operating under a going-concern warning with a cash runway that was projected to end around August 2026, and it only recently regained Nasdaq compliance after a 1-for-15 reverse split. Accelerating commercial traction is the clearest path to extending runway without further dilutive financing.
How filings like this one have moved
In the 30 days to Oct 6, 2026, 28.9% of the 1573 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $5.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $4.56 to $80.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.